Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Lansoprazole
gptkb:Protonix gptkb:Nexium_IV |
| gptkbp:activities |
inhibits platelet aggregation
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:1997
gptkb:FDA |
| gptkbp:brand |
gptkb:Plavix
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
pregnancy
severe liver disease active bleeding severe renal impairment lactation |
| gptkbp:developed_by |
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb |
| gptkbp:dosage_form |
300 mg loading dose
75 mg tablet |
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
Clopidogrel
|
| gptkbp:ingredients |
C16 H16 Cl N2 O2 S
|
| gptkbp:interacts_with |
gptkb:esomeprazole
gptkb:omeprazole gptkb:warfarin NSAI Ds |
| gptkbp:is_atype_of |
B01 A C04
|
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_used_for |
preventing blood clots
|
| gptkbp:lifespan |
8 hours
|
| gptkbp:metabolism |
liver
|
| gptkbp:name |
Essential Medicines
|
| gptkbp:side_effect |
bruising
gastrointestinal bleeding diarrhea rash bleeding hepatotoxicity thrombotic thrombocytopenic purpura hypersensitivity reaction |
| gptkbp:suitable_for |
after myocardial infarction
after stent placement after stroke dual antiplatelet therapy |
| gptkbp:treatment |
gptkb:peripheral_artery_disease
ischemic stroke acute coronary syndrome |
| gptkbp:type_of |
113665-84-2
|
| gptkbp:used_in |
gptkb:hospital
stroke prevention percutaneous coronary intervention acute coronary syndrome |